u/joaquin_trevino

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

Disagreeing with this bit: that criterion belongs to one member state and is being quoted as general.

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

Fertility can change with weight loss and improved insulin sensitivity. That is a well-described phenomenon and worth knowing about in advance rather than discovering.

SURPASS is the diabetes programme and reports glycaemic endpoints

PCOS and insulin resistance are the thread that runs through this board

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Insulin resistance is a common feature in PCOS, which is why the metabolic conversation overlaps so heavily with this board. A diagnosis and a finding are still different things and the distinction matters for what the evidence says.

Yes — date of analysis, because a result from two years ago describes a different manufacturing month.

metformin and an incretin agonist are not in competition

Push back: an open-label extension tells you about the people who stayed. That is a different question.

a shortage in one member state is not a shortage in all of them

vendor, compound, batch, service, result — that is the template

Annotation is what makes a log survive contact with your future self. A single note beside an unusual week saves an hour of puzzled reconstruction later.

That trial did not enrol the population you are asking about, so it cannot answer this.

Agreed on quoting the claim alongside the result. Half the arguments here are two people comparing to different reference numbers.

pharmacy margins are regulated differently in each country

Insulin resistance is a common feature in PCOS, which is why the metabolic conversation overlaps so heavily with this board. A diagnosis and a finding are still different things and the distinction matters for what the evidence says.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

the trials were not designed to answer most of the questions asked here

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

Is that a first-day sensor reading?

Correcting myself: 22 weeks between those two A1c results, which is too short an interval to interpret.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Do you have the publication or the press release?

Absolute or relative risk reduction?

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

a log with no dates is a story

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

Adding the obvious one — bring the export, not the single number, to whoever manages this.

DEXA has a meaningful coefficient of variation, and it differs between machines and protocols. Comparing scans from different clinics adds a systematic offset that is invisible on the report.

Kept one line a week for 11 months.

Agreed — and the payoff genuinely arrives in month six, not week two.

Yes.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

Sent a vial in specifically to check a supplier’s claim after a good experience. It matched. Boring result, worth logging.

trial populations get support that nobody on this board gets

Is that a first-day sensor reading?

A1c is a three-month average and it lags everything

Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.